Doxylamine

From Wikipedia, the free encyclopedia - View original article

Doxylamine
Doxylamine.svg
Systematic (IUPAC) name
(RS)-N,N-dimethyl-2- (1-phenyl-1-pyridin-2-yl-ethoxy)- ethanamine
Clinical data
Trade namesUnisom
AHFS/Drugs.commonograph
MedlinePlusa682537
Pregnancy cat.A (AU) B (US) A (Briggs)
Legal statusPharmacist Only (S3) (AU) OTC (US)
RoutesOral
Pharmacokinetic data
BioavailabilityOral: 24.7%, Intranasal: 70.8% [1]
MetabolismHepatic
Half-life6–12 hours
ExcretionUrine; 60%, faeces; 40%[2]
Identifiers
CAS number469-21-6 YesY
ATC codeR06AA09
PubChemCID 3162
DrugBankDB00366
ChemSpider3050 YesY
UNII95QB77JKPL YesY
KEGGD07878 YesY
ChEBICHEBI:51380 YesY
ChEMBLCHEMBL1004 YesY
Chemical data
FormulaC17H22N2O 
Mol. mass270.369 g/mol
 YesY (what is this?)  (verify)
 
Jump to: navigation, search
Doxylamine
Doxylamine.svg
Systematic (IUPAC) name
(RS)-N,N-dimethyl-2- (1-phenyl-1-pyridin-2-yl-ethoxy)- ethanamine
Clinical data
Trade namesUnisom
AHFS/Drugs.commonograph
MedlinePlusa682537
Pregnancy cat.A (AU) B (US) A (Briggs)
Legal statusPharmacist Only (S3) (AU) OTC (US)
RoutesOral
Pharmacokinetic data
BioavailabilityOral: 24.7%, Intranasal: 70.8% [1]
MetabolismHepatic
Half-life6–12 hours
ExcretionUrine; 60%, faeces; 40%[2]
Identifiers
CAS number469-21-6 YesY
ATC codeR06AA09
PubChemCID 3162
DrugBankDB00366
ChemSpider3050 YesY
UNII95QB77JKPL YesY
KEGGD07878 YesY
ChEBICHEBI:51380 YesY
ChEMBLCHEMBL1004 YesY
Chemical data
FormulaC17H22N2O 
Mol. mass270.369 g/mol
 YesY (what is this?)  (verify)

Doxylamine is a first generation antihistamine. It can be used by itself as a short-term sedative and in combination with other drugs to provide night-time allergy and cold relief. Doxylamine is also used in combination with the analgesics paracetamol (acetaminophen) and codeine as an analgesic/calmative preparation, and is prescribed in combination with vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women. Its foetal safety is "A" in Briggs' Reference Guide to Foetal and Neonatal Risk.[3]

Indications[edit]

Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power superior to almost every other antihistamine on the market, with the exception of diphenhydramine (Benadryl); it is also the most effective over-the-counter sedative available in the United States and is more sedating than some prescription hypnotics.[4] One study found that doxylamine succinate was more effective than the barbiturate phenobarbital for use as a sedative.[4]

The dosage required to induce sleep can be as low as 6.25 mg, but is usually effective in dosages of up to 25 mg. Higher doses are not recommended by the United States Food and Drug Administration, although single dosage recommendations of up to 50 mg are common in some countries, including Australia, where it is marketed under the names Restavit and Dozile. A recent placebo-controlled, double-blind randomized trial found the formulation of doxylamine and pyridoxine marketed as Diclegis to be effective in controlling nausea and vomiting due to pregnancy.[5]

Metabolites[edit]

The main metabolites are N-desmethyldoxylamine, N,N-didesmethyldoxylamine, and doxylamine N-oxide.[6][7]

Side effects[edit]

Doxylamine succinate is a potent anticholinergic and has a side-effect profile common to such drugs, including dry mouth, ataxia, urinary retention, drowsiness, memory problems, inability to concentrate, hallucinations, psychosis, and a marked increased sensitivity to external stimuli. Like many hypnotics, it should not be combined with other antihistamines,[citation needed] such as Zyrtec (cetirizine) or Benadryl (diphenhydramine), as this combination can increase the risk of serious side effects. Using doxylamine over a long period of time is not recommended. However, the drug is not addictive, and withdrawal effects are unlikely to be experienced with prolonged use.

Toxicity[edit]

Doxylamine succinate is generally safe for administration to healthy adults. Typical preparations that contain doxylamine range from 6.25 mg to 50 mg. The Median Lethal Dose ( LD50) is estimated to be 50–500 mg/kg in humans.[8] Symptoms of overdose may include dry mouth, dilated pupils, insomnia, night terrors, euphoria, hallucinations, seizures, rhabdomyolysis, and death.[9] Fatalities have been reported from doxylamine overdose. These have been characterized by coma, tonic-clonic (or grand mal) seizures and cardiorespiratory arrest. Children appear to be at a high risk for cardiorespiratory arrest. A toxic dose for children of more than 1.8 mg/kg has been reported. A 3-year old child died 18 hours after ingesting 1,000 mg doxylamine succinate.[2] Rarely, an overdose results in rhabdomyolysis and acute renal failure.[10]

Studies of doxylamine's carcinogenicity in mice and rats have produced positive results for both liver and thyroid cancer, especially in the mouse.[11] The carcinogenicity of the drug in humans is not well studied, and the IARC lists the drug as "not classifiable as to its carcinogenicity to humans".[12]

Formulations[edit]

Doxylamine is primarily used as the succinic acid salt, doxylamine succinate.

References[edit]

  1. ^ http://www3.interscience.wiley.com/journal/98016819/abstract
  2. ^ a b http://www.medsafe.govt.nz/profs/datasheet/d/Dozilecap.pdf
  3. ^ Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 8th edition. 2008. Published by: Lippincott Williams & Wilkins.
  4. ^ a b http://www.drugbank.ca/drugs/DB00366
  5. ^ http://www.ncbi.nlm.nih.gov/pubmed?term=Am%20J%20Obstet%20Gynecol.%202010%20AND%20diclectin
  6. ^ Holder, C. L.; Korfmacher, W. A.; Slikker Jr, W.; Thompson Jr, H. C.; Gosnell, A. B. (1985). "Mass spectral characterization of doxylamine and its rhesus monkey urinary metabolites". Biomedical mass spectrometry 12 (4): 151–158. PMID 2861861.  edit
  7. ^ http://www.rxlist.com/khedezla-drug/clinical-pharmacology.htm
  8. ^ http://hazard.com/msds/mf/baker/baker/files/d8882.htm
  9. ^ Syed, Husnain; Sumit Som, Nazia Khan, Wael Faltas (17 March 2009). "Doxylamine toxicity: seizure, rhabdomyolysis and false positive urine drug screen for methadone". BMJ Case Reports (BMJ Group) 2003 (90): 845. doi:10.1136/bcr.09.2008.0879. Retrieved 29 November 2009. 
  10. ^ Leybishkis B, B; Fasseas P; Ryan KF. (July 2001). "Doxylamine overdose as a potential cause of rhabdomyolysis". American journal of the medical sciences (Lippincott Williams & Wilkins) 322 (1): 48–9. doi:10.1097/00000441-200107000-00009. PMID 11465247. 
  11. ^ http://potency.berkeley.edu/chempages/DOXYLAMINE%20SUCCINATE.html
  12. ^ http://www.inchem.org/documents/iarc/vol79/79-05.html
  13. ^ manufacturer's website